secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001193125-26-029705
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology amends bylaws to update advance notice, quorum, indemnification provisions
--------------------------------------------------------------------------------

- Updated advance notice: annual meeting date shift threshold extended to >70 days (previously 30) before alternative notice window applies.
- Quorum threshold changed from majority of outstanding shares to majority of voting power; default approval changed to majority of votes cast.
- Incorporated universal proxy rules (Rule 14a-19); limited shareholder nominations to number of directors to be elected, no substitute nominees.
- Enhanced forum selection: Delaware federal courts as backup for state court actions; added exclusive forum for Securities Act claims.
- Expanded mandatory indemnification for directors/officers to maximum extent allowed by law; added expense advancement procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/d18498d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-029705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer